Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatment

De la Sancha, CarloBurgin, CallieWarren, SimonHoffmann, KristinDavé, UtpalNassiri, Mehdi2022-04-202022-04-202020-12De la Sancha, C., Burgin, C., Warren, S., Hoffmann, K., Davé, U., & Nassiri, M. (2020). Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatment. JAAD case reports, 6(12), 1342–1344. https://doi.org/10.1016/j.jdcr.2020.08.041https://hdl.handle.net/1805/28614Primary cutaneous peripheral T-cell lymphoma, not otherwise specified (pcPTCL-NOS) is a rare, progressive, and often fatal disease with no specific treatment regimen that presents as rapidly enlarging plaques or nodules. Here, we present a case of progressive pcPTCL-NOS with mammalian target of rapamycin (mTOR) mutation and variable T-cell antigen expression. mTOR mutation in pcPTCL-NOS may represent a new therapeutic target.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalBCL6 corepressorMammalian target of rapamycinPrimary cutaneous peripheral T-cell lymphomaPrimary cutaneous lymphomaPrimary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatmentArticle